Initiation of Statins After Hospitalization for Coronary Heart Disease

Gross, Cynthia R.; Schommer, Jon C.; Cline, Richard R.; Xuan, Jianwei; St, Wendy L.

doi:10.18553/jmcp.2007.13.5.385

Cited by 20 publications

(15 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…33 However,Y eet al reported recently that the proportion of patients who received as tatin after aC HD hospitalization increased in each of 4y ears to an average 56% of patients in 2003. 34 Second, we defined continuous treatment broadly.C ontinuous treatment could have been as few as 2p harmacy claims (i.e., 2m onths of treatment) for al ipid-modifying drug in the first 12 months of follow up although the median was 7months and at least 1fill was required in each time period.…”

Section: Nn Discussionmentioning

confidence: 99%

LDL-C goal Attainment Among Patients Newly Diagnosed With Coronary Heart Disease or Diabetes in a Commercial HMO

Nag¹,

Daniel²,

Bullano³

et al. 2007

JMCP

View full text Add to dashboard Cite

Section: Nn Discussionmentioning

confidence: 99%

LDL-C goal Attainment Among Patients Newly Diagnosed With Coronary Heart Disease or Diabetes in a Commercial HMO

Nag¹,

Daniel²,

Bullano³

et al. 2007

JMCP

View full text Add to dashboard Cite

“…MarketScan has formed the basis of more than 250 peerreviewed publications. 17,18 In compliance with the Health Insurance Portability and Accountability Act, all patient data were de-identified.…”

Section: Study Design and Databasesmentioning

confidence: 99%

Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA‐Like Patients With Atrial Fibrillation/Atrial Flutter in the United States

Naccarelli

Johnston

Lin

et al. 2010

Clinical Cardiology

View full text Add to dashboard Cite

Background: The ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) demonstrated that dronedarone reduced the risk of cardiovascular (CV) hospitalization/death by 24% (P < 0.001) in patients with atrial fibrillation (AF) and atrial flutter (AFL). Hypothesis: In order to estimate the cost savings associated with dronedarone use, we estimated the costs associated with CV hospitalizations and inpatient mortality in a large cohort of ATHENA-like patients. Methods: In this retrospective analysis, we evaluated the cost of CV hospitalization/mortality in real-world ATHENA-like patients without heart failure and with employer-sponsored Medicare supplemental insurance in the United States. Patients similar to those in ATHENA (age ≥70 years with AF/AFL and ≥1 stroke risk factor, without heart failure) who were hospitalized between January 2, 2005, and January 1, 2007, were identified from the MarketScan databases from Thomson Reuters. Health care costs were evaluated during the 12 months following the index hospitalization. Results: The analysis included 10 200 ATHENA-like patients.Hospitalization for CV causes occurred in 53.9% of patients, with a total of 6700 CV hospitalizations for fatal/nonfatal causes. The most common nonfatal causes of CV hospitalizationswere AF/other supraventricular rhythm disorders (20.2% of all CV hospitalizations),congestive heart failure (CHF; 14.3%), and transient ischemic attack (TIA)/stroke (10.7%). Mean costs per CV hospitalization for nonfatal causes were $10908. Inpatient deaths from CV causes occurred in 264 (2.6%) patients; the most common causes of CV inpatient death were intracranial/gastrointestinal hemorrhage (24.2% of CV deaths), TIA/stroke (17.0%), and CHF (15.9%). Mean hospitalizationcosts per CV inpatient death were $18 565. Conclusions: Health care costs associated with CV hospitalizations and inpatient deaths among ATHENA-like patients in the US are high. Novel antiarrhythmic therapies such as dronedarone, with the potential to reduce CV hospitalizations/mortality in similar patients, could decrease health care costs if adopted in clinical practice.

show abstract

“…16 The MarketScan dataset has been used by many other researchers investigating the health and economic burden of CVD. 7,[17][18][19][20][21] Using codes from the International Classification of Diseases, 9 th revision (ICD-9) (Table 1), we identified hospitalizations with a primary or secondary diagnosis of IHD among patients aged 18 to 64 years enrolled in non-capitated health insurance plans. We excluded patients younger than 18 because of the low prevalence of IHD in that age group.…”

Section: Methodsmentioning

confidence: 99%

Inpatient Costs Associated with Ischemic Heart Disease Among Adults Aged 18-64 Years in the United States

Wang¹,

Zhang²,

Ayala³

et al. 2012

Novel Strategies in Ischemic Heart Disease

View full text Add to dashboard Cite

Initiation of Statins After Hospitalization for Coronary Heart Disease

Abstract: What is already known about this subject• Previous research has shown that as much as 60% of patients with a diagnosis of CHD do not receive lipid-modifying therapy in the ambulatory care setting.

Cited by 20 publications

References 43 publications

LDL-C goal Attainment Among Patients Newly Diagnosed With Coronary Heart Disease or Diabetes in a Commercial HMO

LDL-C goal Attainment Among Patients Newly Diagnosed With Coronary Heart Disease or Diabetes in a Commercial HMO

Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA‐Like Patients With Atrial Fibrillation/Atrial Flutter in the United States

Inpatient Costs Associated with Ischemic Heart Disease Among Adults Aged 18-64 Years in the United States

Contact Info

Product

Resources

About